SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUERS PURSUANT TO RULE
13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT
OF 1934
Dated: March 1, 2004
Commission file number 0-21392
AMARIN CORPORATION PLC
(Exact name of Registrant as Specified in its Charter)
ENGLAND
(Jurisdiction of Incorporation or
organization of Issuer)
7 Curzon Street
London W1J 5HG, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or
Form 40-F.
[X] Form 20-F [ ] Form 40-F
Indicate by check mark whether the registrant by
furnishing the information contained in this Form is
also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
[ ] Yes [X] No
Attachment:
Material Events
(a) Resignation of Amarin Officers following Asset Sale to
Valeant Pharmaceuticals International.
This report on Form 6-K is hereby incorporated by reference in
(a) the registration statement on Form F-3 (Registration No.
333-104748) of Amarin Corporation plc and in the prospectus
contained therein, (b)the registration statement on Form F-3
(Registration No. 333-13200) of Amarin Corporation plc and in
the prospectus contained therein and (c)the registration
statement on Form F-3 (Registration No.333-12642) of Amarin
Corporation plc and in the prospectus contained therein, and
this report on Form 6-K shall be deemed a part of each such
registration statement from the date on which this report is
filed, to the extent not superseded by documents or reports
subsequently filed or furnished by Amarin Corporation plc under
the Securities Act of 1933 or the Securities Exchange Act of
1934.
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AMARIN CORPORATION PLC
By:/s/Richard A B Stewart
Richard A B Stewart
Chief Executive Officer
Date: March 1, 2004
Index to Exhibits
Exhibit Item Sequentially Numbered Page
(a) Material Event description- 4
Exhibit (a)
Contact:
Rick Stewart
Chief Executive Officer
Amarin Corporation plc
Phone: +44 (0) 207 907 2442
investor.relations@amarincorp.com
Ian Garland
Chief Financial Officer
Amarin Corporation plc
Phone +44 (0) 207 907 2444
investor.relations@amarincorp.com
RESIGNATION OF AMARIN OFFICERS FOLLOWING ASSET SALE TO
VALEANT PHARMACEUTICALS INTERNATIONAL
LONDON, United Kingdom, March 1, 2004: Amarin Corporation plc
NASDAQ: AMRN) today announced the resignation of three of its senior
executives following the sale of its U.S. based subsidiary, Amarin
Pharmaceuticals, Inc. and a majority of its U.S. products to Valeant
Pharmaceuticals International (NYSE: VRX). Michael D. Coffee,
Director, President and Chief Operating Officer, Donald R. Joseph,
Executive Vice President commercial development and Steve Guillen,
Vice President of sales and marketing have all resigned from
Amarin with immediate effect.
For press releases and other corporate information, visit our
website at http://www.amarincorp.com.
Statements in this press release that are not historical
facts are forward-looking statements that involve risks and
uncertainties which may cause the Company's actual results in
future periods to be materially different from any performance
suggested herein. Such risks and uncertainties include, without
limitation, the uncertainty of entering into and consummating a
definitive agreement on terms acceptable to the parties, the
inherent uncertainty of pharmaceutical research, product
development and commercialization, the impact of competitive
products and patents, as well as other risks and uncertainties
detailed from time to time in periodic reports. For more
information, please refer to Amarin Corporation's Annual Report
for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S.
Securities and Exchange Commission. Amarin Corporation assumes no
obligation to update information on its expectations.